Clinical Trial Reveals Neuropaway is " significantly effective" in "reducing pain... related to the diabetic peripheral neuropathy."

Clinical Trial Reveals Neuropaway is " significantly effective" in "reducing pain... related to the diabetic peripheral neuropathy."

READ THE CLINICAL STUDY HERE!

VasoCorp, a Georgia for profit corporation, on a mission to change the standard of care for those suffering from neuropathic discomfort by proving the efficacy of a dietary supplement formula, announced today the results from their Phase I clinical trial. VasoCorp is making life better for those in need of an alternative solution to the harsh prescription drugs that are now used to deal with this condition. 

The trial was authored by William Cross, President and Founder of VasoCorp, and Dr. Shalini Srivastava, Vedic Life Sciences, Mumbai India. Mr. Cross has a record of research on innovative ideas and basic-science discoveries. In 2017, Mr. Cross was awarded Young Entrepreneur of the Year by the U.S. Small Business Administration's Georgia District Office who acknowledge that his "efforts...have helped thousands of people ease their debilitating pain."

Back to blog